Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
2024年2月17日 - 2:17PM
ビジネスワイヤ(英語)
Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN)
celebrated commencement of its public trading by ringing the
opening bell at the Nasdaq Stock Exchange in Times Square, New
York, on February 15th, 2024. This major milestone underscored the
company's commitment to its valued shareholders and its mission to
develop commercially attractive, affordable, genetically unmodified
off-the-shelf T cell therapies for large patient populations in
virology, oncology, and neurology.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240216782434/en/
Team Tevogen celebrating listing with
Nasdaq (Photo: Business Wire)
“We are deeply honored to become part of the Nasdaq family, a
significant milestone that highlighted the commitment and
dedication of our team,” remarked Ryan Saadi, MD, MPH, Chief
Executive Officer of Tevogen Bio. “This event not only reconfirmed
company’s growth strategy but also reinforced our commitment to our
mission. As we embark on this new chapter, we look forward to
contributing to the market's vibrancy and delivering value to our
shareholders and patients.”
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Leadership believes that sustainability and commercial
success in the current era of healthcare rely on ensuring patient
accessibility through advanced science and innovative business
models. Tevogen has reported positive safety data from its
proof-of-concept clinical trial, and its key intellectual property
assets are wholly owned by the company, not subject to any
third-party licensing agreements. These assets include three
granted patents and twelve pending patents, two of which are
related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry
leaders and distinguished scientists with drug development and
global product launch experience. Tevogen Bio’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
Forward-Looking Statements
This press release contains certain statements that are not
historical facts and are forward-looking statements within the
meaning of the federal securities laws, including without
limitation statements regarding the anticipated benefits of the
recent business combination with Semper Paratus Acquisition
Corporation (the “Business Combination”), the future financial
condition and performance of Tevogen Bio, and the product
candidates, products, markets, and expected future performance and
market opportunities of Tevogen Bio. These forward-looking
statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,” “think,”
“strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,”
“may,” “should,” “will,” “would,” “will be,” “will continue,” “will
likely result,” and similar expressions, but the absence of these
words does not mean that a statement is not forward-looking.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties.
Factors that could cause actual future events to differ
materially from the forward-looking statements in this
communication include without limitation: (i) the effect of the
announcement of the Business Combination on Tevogen Bio’s business
relationships, operating results, and business generally; (ii) the
outcome of any legal proceedings that may be instituted against
Tevogen Bio related to the Merger Agreement or the Business
Combination ; (iii) changes in the markets in which Tevogen Bio
competes, including with respect to its competitive landscape,
technology evolution, or regulatory changes; (iv) changes in
domestic and global general economic conditions; (v) risk that
Tevogen Bio may not be able to execute its growth strategies or may
experience difficulties in managing its growth and expanding
operations; (vi) risk that Tevogen Bio may not be able to develop
and maintain effective internal controls; (vii) costs related to
the Business Combination and the failure to realize anticipated
benefits of the Business Combination or to realize estimated pro
forma results and underlying assumptions, including with respect to
estimated shareholder redemptions; (viii) the failure to recognize
the anticipated benefits of the Business Combination and to achieve
Tevogen Bio’s commercialization and development plans, and identify
and realize additional opportunities, which may be affected by,
among other things, competition, the ability of Tevogen Bio to grow
and manage growth economically and hire and retain key employees;
(ix) the risk that Tevogen Bio may fail to keep pace with rapid
technological developments to provide new and innovative products
and services or make substantial investments in unsuccessful new
products and services; (x) the ability to develop, license or
acquire new therapeutics; (xi) the risk that Tevogen Bio will need
to raise additional capital to execute its business plan, which may
not be available on acceptable terms or at all; (xii) the risk of
product liability or regulatory lawsuits or proceedings relating to
Tevogen Bio’s business; (xiii) uncertainties inherent in the
execution, cost, and completion of preclinical studies and clinical
trials; risks related to regulatory review, and approval and
commercial development; (xiv) risks associated with intellectual
property protection; (xv) Tevogen Bio’s limited operating history;
and (xvi) those factors discussed in Tevogen Bio’s filings with the
SEC and that that are contained in the Proxy Statement/Prospectus
relating to the Business Combination.
The foregoing list of factors is not exhaustive. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of the Proxy
Statement/Prospectus and other documents to be filed by Tevogen Bio
from time to time with the SEC. These filings identify and address
other important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and while Tevogen Bio
may elect to update these forward-looking statements at some point
in the future, they assume no obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240216782434/en/
Tevogen Communications T: 1 877 TEVOGEN, Ext 701
communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
過去 株価チャート
から 4 2024 まで 5 2024
Tevogen Bio (NASDAQ:TVGN)
過去 株価チャート
から 5 2023 まで 5 2024